SOUTH SAN FRANCISCO, Calif.
/PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) announced today that on
July 20, 2010
it received a letter from the Nasdaq Stock Market stating that the minimum bid price of the Company's common stock has been below
per share for 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued listing set forth in Marketplace Rule [5450(a)(1)]. The notification of noncompliance has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Market.
The Company has been provided 180 calendar days, or until
January 18, 2011
, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed
per share for at least ten consecutive business days during this 180-day grace period. Nasdaq may, in its discretion, require the Company's common stock to maintain a closing bid price of at least
for a period in excess of ten consecutive trading days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.
If the Company does not regain compliance by
January 18, 2011
, it will receive written notification from Nasdaq that its common stock is subject to delisting. The Company may, at that time, appeal the delisting determination to a Nasdaq Hearings Panel. Such an appeal, if granted, would stay delisting until a Panel ruling. Alternatively, if at that time the Company satisfies all of the initial listing standards, with the exception of the minimum bid price, for the Nasdaq Capital Market, the Company could apply to transfer the listing of its common stock to the Nasdaq Capital Market and thereby receive an additional 180 calendar days to regain compliance with the minimum bid price requirement.
The Company will consider available options to resolve the minimum bid price deficiency and regain compliance with the Nasdaq minimum bid price requirement. There can be no assurance that the Company will be able to regain or maintain compliance with the minimum bid price rule or other listing criteria or that an appeal, if taken, would be successful.